CAH is well-poised for growth, given its long-term supply agreements, diversified product portfolio and strong quarterly earnings. However, the possibility of losing a major customer remains a risk.

My message to everyone is simple—take the first step, seek professional advice, and remember, "The best investment you can ...

“While the data to date are not yet transformational, the study showed for the first time that people living with CAH can indeed make their own cortisol, and that gene therapy can be safely ...

Primary care clinicians are often the most accessible to patients and play a crucial role in the early detection and ...

PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly ...

With Neurocrine Biosciences having finally shaken up treatment for a rare genetic hormone disease ... for a range of disorders including congenital adrenal hyperplasia (CAH).

Weakness in the Magnificent Seven stocks and a slide in chip stocks led to a rout in megacap technology stocks Tuesday that weighed on the broader market. Stocks remained under pressure Tuesday ...